Key Data:
Location
Metro, Montreal, Quebec, Canada
Estimated Investment
$460m
Completion
Phase 1 – 2004/2005; 2006 plant mothballed for foreseeable future
Key Players:
Lead engineer / designer
SNC-Lavalin Pharma (SLP)
Building constructor
JE Verreault
Bioreactor design and construction
Biolafitte (Pierre Guérin)
Control systems
SNC-Lavalin pharma (SLP)
Financing
SGF (Societe Generale de Financement du Quebec) - $91m
Province of Quebec - $33m
Output Chemicals:
Type
Recombinant Proteins, Monoclonal Antibodies